Chemoisosterism in the proteome

Journal of Chemical Information and Modeling

Volumn 53, Issue 2, 2013, Pages 279-292

  Jalencas, Xavier ^a   Mestres, Jordi ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEXATION; LIGANDS;

CHEMICAL FRAGMENTS; COMPLEMENTARY PROPERTY; DRUG DISCOVERY; ENZYME STRUCTURES; NUCLEAR RECEPTORS; PROTEIN-LIGAND COMPLEXES;

PROTEINS;

LIGAND; PROTEIN; PROTEOME;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; METHODOLOGY; PROTEIN DATABASE;

DATABASES, PROTEIN; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEINS; PROTEOME;

EID: 84874406294     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci3002974     Document Type: Article

References (51)

1. Rose, P. W.; Beran, B.; Bi, C.; Bluhm, W. F.; Dimitropoulos, D.; Goodsell, D. S.; Prlic, A.; Quesada, M.; Quinn, G. B.; Westbrook, J. D.; Young, J.; Yukich, B.; Zardecki, C.; Berman, H. M.; Bourne, P. E. The RCSB Protein Data Bank: Redesigned web site and web services Nucleic Acids Res. 2011, 39, D392-401
2. Mestres, J. Representativity of target families in the Protein Data Bank: Impact for family-directed structure-based drug discovery Drug Discovery Today 2005, 10, 1629-37
3. Weigelt, J. Structural genomics-impact on biomedicine and drug discovery Exp. Cell Res. 2010, 316, 1332-1338
4. Hubbard, R. E. Structure-based drug discovery and protein targets in the CNS Neuropharmacology 2011, 60, 7-23
5. Hendlich, M.; Bergner, A.; Günther, J.; Klebe, G. Relibase: Design and development of a database for comprehensive analysis of protein-ligand interactions J. Mol. Biol. 2003, 326, 607-620
6. Bruno, I. J.; Cole, J. C.; Lommerse, J. P.; Rowland, R. S.; Taylor, R.; Verdonk, M. L. IsoStar: A library of information about nonbonded interactions J. Comput.-Aided Mol. Des. 1997, 11, 525-537
7. Kennewell, E. A.; Willett, P.; Ducrot, P.; Luttmann, C. Identification of target-specific bioisosteric fragments from ligand-protein crystallographic data J. Comput.-Aided Mol. Des. 2006, 20, 385-394
8. Langdon, S. R.; Ertl, P.; Brown, N. Bioisosteric replacement and scaffold hopping in lead generation and optimization Mol. Inf. 2010, 29, 366-385
9. Sheridan, R. P. The most common chemical replacements in drug-like compounds J. Chem. Inf. Comput. Sci. 2002, 42, 103-108
10. Southall, N. T. Ajay kinase patent space visualization using chemical replacements J. Med. Chem. 2006, 49, 2103-2109
11. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591
12. Hert, J.; Keiser, M. J.; Irwin, J. J.; Oprea, T. I.; Shoichet, B. K. Quantifying the relationships among drug classes J. Chem. Inf. Model. 2008, 48, 755-765
13. Briansó, F.; Carrascosa, M. C.; Oprea, T. I.; Mestres, J. Cross-pharmacology analysis of G protein-coupled receptors Curr. Top. Med. Chem. 2011, 11, 1956-1963
14. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136
15. Milletti, F.; Vulpetti, A. Predicting polypharmacology by binding site similarity: from kinases to the protein universe J. Chem. Inf. Model. 2010, 50, 1418-1431
16. Garcia-Serna, R.; Mestres, J. Anticipating drug side effects by comparative pharmacology Expert Opin. Drug Metab. Toxicol. 2010, 6, 1253-1263
17. Wang, X.; Greene, N. Comparing measures of promiscuity and exploring their relationship to toxicity Mol. Inf. 2012, 31, 145-159
18. Wang, R.; Fang, X.; Lu, Y.; Wang, S. The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures J. Med. Chem. 2004, 47, 2977-2980
19. Wagener, M.; Lommerse, J. P. M. The quest for bioisosteric replacements J. Chem. Inf. Model. 2006, 46, 677-685
20. Zauhar, R. J. SMART: A solvent-accessible triangulated surface generator for molecular graphics and boundary element applications J. Comput.-Aided Mol. Des. 1995, 9, 149-159
21. Schmitt, S.; Kuhn, D.; Klebe, G. A new method to detect related function among proteins independent of sequence and fold homology J. Mol. Biol. 2002, 323, 387-406
22. Shulman-Peleg, A.; Nussinov, R.; Wolfson, H. J. Recognition of functional sites in protein structures J. Mol. Biol. 2004, 339, 607-33
23. Gold, N. D.; Jackson, R. M. SitesBase: A database for structure-based protein-ligand binding site comparisons Nucleic Acids Res. 2006, 34, D231-4
24. Kufareva, I.; Ilatovskiy, A. V.; Abagyan, R. Pocketome: An encyclopedia of small-molecule binding sites in 4D Nucleic Acids Res. 2012, 40, D535-540
25. Ito, J.-I.; Tabei, Y.; Shimizu, K.; Tsuda, K.; Tomii, K. PoSSuM: A database of similar protein-ligand binding and putative pockets Nucleic Acids Res. 2012, 40, D541-548
26. Niskanen, S.; ÖstergaÌŠrd, P. R. J. Cliquer User's Guide, Version 1.0; Communications Laboratory, Helsinki University of Technology: Espoo, Finland, 2003.
27. Mestres, J.; Maggiora, G. Putting molecular similarity into context: Asymmetric indices for field-based similarity measures J. Math. Chem. 2006, 39, 107-118
28. Gregori-Puigjané, E.; Garriga-Sust, R.; Mestres, J. Indexing molecules with chemical graph identifiers J. Comput. Chem. 2011, 32, 2638-2646
29. Oprea, T. I. Property distribution of drug-related chemical databases J. Comput.-Aided Mol. Des. 2000, 14, 251-264
30. Hastie, T.; Tibshirani, R.; Friedman, J. The Elements of Statistical Learning; Springer Series in Statistics; Springer: New York, 2009; pp 485-586.
31. Vogt, I.; Mestres, J. Drug-Target Networks Mol. Inf. 2010, 29, 10-14
32. Mestres, J.; Gregori-Puigjané, E.; Valverde, S.; Solé, R. V. The topology of drug-target interaction networks: implicit dependence on drug properties and target families Mol. BioSyst. 2009, 5, 1051-1057
33. Edfeldt, F. N. B.; Folmer, R. H. A.; Breeze, A. L. Fragment screening to predict druggability (ligandability) and lead discovery success Drug Discovery Today 2011, 16, 284-287
34. Surade, S.; Blundell, T. L. Structural biology and drug discovery of difficult targets: The limits of ligandability Chem. Biol. 2012, 19, 42-50
35. Nobeli, I.; Favia, A. D.; Thornton, J. M. Protein promiscuity and its implications for biotechnology Nat. Biotechnol. 2009, 27, 157-167
36. Liao, J. J.-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50, 409-424
37. Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. DrugBank 3.0: A comprehensive resource for "omics" research on drugs Nucleic Acids Res. 2011, 39, D1035-1041
38. Gleeson, M. P.; Hersey, A.; Montanari, D.; Overington, J. Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discovery 2011, 10, 197-208
39. Li, Q.; Cheng, T.; Wang, Y.; Bryant, S. H. PubChem as a public resource for drug discovery Drug Discovery Today 2010, 15, 1052-1057
40. Weber, A.; Casini, A.; Heine, A.; Kuhn, D.; Supuran, C. T.; Scozzafava, A.; Klebe, G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition J. Med. Chem. 2004, 47, 550-557
41. Kalinina, O. V.; Wichmann, O.; Apic, G.; Russell, R. B. Combinations of protein-chemical complex structures reveal new targets for established drugs PLoS Comput. Biol. 2011, 7, e1002043
42. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility J. Comput. Chem. 2009, 30, 2785-2791
43. Schubert, C. R.; Stultz, C. M. The multi-copy simultaneous search methodology: A fundamental tool for structure-based drug design J. Comput.-Aided Mol. Des. 2009, 23, 475-489
44. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192
45. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules Nat. Rev. Drug Discovery 2005, 4, 649-663
46. Chessari, G.; Woodhead, A. J. From fragment to clinical candidate-A historical perspective Drug Discovery Today 2009, 14, 668-675
47. Yang, P.; Li, X.; Wu, M.; Kwoh, C.-K.; Ng, S.-K. Inferring gene-phenotype associations via global protein complex network propagation PLoS ONE 2011, 6, e21502
48. Campillos, M.; Kuhn, M.; Gavin, A.-C.; Jensen, L. J.; Bork, P. Drug target identification using side-effect similarity Science 2008, 321, 263-266
49. Vidal, D.; Garcia-Serna, R.; Mestres, J. Ligand-based approaches to in silico pharmacology Methods Mol. Biol. 2011, 672, 489-502
50. Kawatkar, S.; Wang, H.; Czerminski, R.; Joseph-McCarthy, D. Virtual fragment screening: An exploration of various docking and scoring protocols for fragments using Glide J. Comput.-Aided Mol. Des. 2009, 23, 527-539
51. Englert, L.; Silber, K.; Steuber, H.; Brass, S.; Over, B.; Gerber, H.-D.; Heine, A.; Diederich, W. E.; Klebe, G. Fragment-based lead discovery: Screening and optimizing fragments for thermolysin inhibition ChemMedChem 2010, 5, 930-940